Skip to main content
. 2012 Feb;56(2):825–829. doi: 10.1128/AAC.05037-11

Fig 2.

Fig 2

Mean (± SD) plasma concentration-time profiles of sulfamethoxazole in renal transplant recipients with the NAT2 rapid acetylator (RA; white circles) (n = 56), NAT2 intermediate acetylator (IA; gray circles) (n = 47), and NAT2 slow acetylator (SA; black circles) (n = 15) genotypes on day 14 after once-a-day administration of 400 mg/day-80 mg/day of sulfamethoxazole-trimethoprim.